drugset
drugset / Trial / NCT02016261

Study to Evaluate Cognitive Functioning in Remitted Depression During Treatment With Fluvoxamine

NCT02016261 ↗

Phase 4 Completed 50 enrolled Moscow Research Institute of Psychiatry Abbott · collab
NaSingle-groupOpen-labelTreatment

Summary

Open label, non-comparative, prospective study to evaluate cognitive functioning in remitted depression outpatients during long-term preventive treatment with Fluvoxamine (Fevarin®)

Timeline

Start
2013-12
Primary completion
2015-07
Completion
2015-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Fluvoxamine Unknown 50 mg —
Subject Fluvoxamine Unknown 300 mg —

Indications

major depressive disorder